Literature DB >> 20466340

Echocardiographic dyssynchrony and health status outcomes from cardiac resynchronization therapy: insights from the PROSPECT trial.

Paul S Chan1, Taiyeb Khumri, Eugene S Chung, Stefano Ghio, Kimberly J Reid, Bart Gerritse, Brahmajee K Nallamothu, John A Spertus.   

Abstract

OBJECTIVES: This study sought to assess the prognostic utility of echocardiographic dyssynchrony for health status improvement after cardiac resynchronization therapy (CRT).
BACKGROUND: Echocardiographic measures of dyssynchrony have been proposed for patient selection for CRT, but prospective validation studies are lacking.
METHODS: A prospective cohort of 324 patients from 53 centers with moderate to severe heart failure, left ventricular dysfunction, QRS > or =130 ms, and available echocardiographic and health status information were identified from the PROSPECT (Predictors of Response to Cardiac Re-Synchronization Therapy) trial, which evaluated the prognostic utility of dyssynchrony measures in CRT recipients. The association of 12 echocardiographic dyssynchrony parameters with 6-month improvement in health status, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), was assessed both as a continuous variable and by responder status (DeltaKCCQ > or =+10 points reflecting moderate to large improvement).
RESULTS: Of 12 pre-defined dyssynchrony parameters, only 3 were consistently reported: interventricular mechanical delay (IVMD), left ventricular filling time relative to the cardiac cycle (LVFT), and left ventricular pre-ejection interval. After multivariable adjustment, IVMD (+5.18, 95% confidence interval [CI]: +0.76 to +9.60; p = 0.02) and LVFT (+5.19, 95% CI: +0.45 to +0.94; p = 0.03) were independently associated with 6-month improvements in KCCQ. Patients with 6-month improvements in KCCQ had lower subsequent mortality (adjusted hazard ratio [HR] for each 5-point improvement: 0.83; 95% CI: 0.72 to 0.93; p = 0.03). Additionally, IVMD was associated with CRT responder status (for DeltaKCCQ > or =+10 points: odds ratio [OR]: 1.85; 95% CI: 1.12 to 3.05; p = 0.03), whereas LVFT was not (OR: 1.63; 95% CI: 0.85 to 3.11; p = 0.14). Patients classified as health status responders had a 76% lower subsequent risk of all-cause mortality (adjusted HR: 0.24; 95% CI: 0.07 to 0.84; p = 0.03).
CONCLUSIONS: The presence of pre-implantation IVMD and LVFT was associated with 6-month health status improvement, and IVMD was associated with a significant CRT response. These echocardiographic factors may help clinicians counsel patients regarding their likelihood of symptomatic improvement with CRT. ( PROSPECT: Predictors of Response to Cardiac Re-Synchronization Therapy; NCT00253357). Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20466340     DOI: 10.1016/j.jcmg.2009.08.012

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  6 in total

Review 1.  Current role of echocardiography in cardiac resynchronization therapy.

Authors:  Donato Mele; Matteo Bertini; Michele Malagù; Marianna Nardozza; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 2.  The relationship between cardiac resynchronization therapy and diastolic function.

Authors:  Gregory F Egnaczyk; Eugene S Chung
Journal:  Curr Heart Fail Rep       Date:  2014-03

3.  Distinct trajectories of disease-specific health status in heart failure patients undergoing cardiac resynchronization therapy.

Authors:  Mirjam H Mastenbroek; Susanne S Pedersen; Mathias Meine; Henneke Versteeg
Journal:  Qual Life Res       Date:  2015-11-13       Impact factor: 4.147

4.  Patient-reported health status prior to cardiac resynchronisation therapy identifies patients at risk for poor survival and prolonged hospital stays.

Authors:  H Versteeg; J Denollet; M Meine; S S Pedersen
Journal:  Neth Heart J       Date:  2016-01       Impact factor: 2.380

Review 5.  Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review.

Authors:  Josep Comín-Colet; Teresa Martín Lorenzo; Almudena González-Domínguez; Juan Oliva; Silvia Jiménez Merino
Journal:  Health Qual Life Outcomes       Date:  2020-10-07       Impact factor: 3.186

6.  The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.

Authors:  Ewa A Jankowska; Bridget-Anne Kirwan; Mikhail Kosiborod; Javed Butler; Stefan D Anker; Theresa McDonagh; Maria Dorobantu; Jarosław Drozdz; Gerasimos Filippatos; Andre Keren; Irakli Khintibidze; Hans Kragten; Felipe A Martinez; Marco Metra; Davor Milicic; José C Nicolau; Marcus Ohlsson; Alexander Parkhomenko; Domingo A Pascual-Figal; Frank Ruschitzka; David Sim; Hadi Skouri; Peter van der Meer; Basil S Lewis; Josep Comin-Colet; Stephan von Haehling; Alain Cohen-Solal; Nicolas Danchin; Wolfram Doehner; Henry J Dargie; Michael Motro; Tim Friede; Vincent Fabien; Fabio Dorigotti; Stuart Pocock; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2021-06-03       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.